Malignant melanoma is the most aggressive and life-threatening skin cancer, the incidence of which continues to rise despite recent therapeutic advances. Owing to these advances, primarily in immuno- and targeted cancer therapies, the malignant melanoma market has become increasingly crowded with novel treatments expanding therapy options for patients, and segmenting the market according to BRAF-mutation status. While heavily dominated by immune checkpoint inhibitors, such as Merck & Co.’s market-leading Keytruda and Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo, opportunities exist for novel agents specifically targeting the underpenetrated adjuvant and BRAF wild-type metastatic setting. With a shift toward combination therapy, doublet and triplet therapy, and the introduction of novel agents for later lines, the malignant melanoma treatment algorithm will continue to evolve. In such a dynamic indication, marketed drugs need to be carefully positioned to achieve optimal uptake.
- How large are the clinically and commercially relevant drug-treatable malignant melanoma populations and how will drug-treatment rates change over time?
- What is the current state of treatment in malignant melanoma? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
- What pipeline products are most promising, and what sales/uptake could they secure in the malignant melanoma market? What does the early-phase pipeline look like?
- What are the drivers and constraints in the malignant melanoma market, and how will the market evolve over the forecast period?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.